{"filing":{"accession_number":"0001213900-26-088068","cik":"0001851484","ticker":"CTOR","company_name":"CITIUS ONCOLOGY, INC.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-07","primary_document":"ea0301456-8k_citius.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1851484/000121390026088068/ea0301456-8k_citius.htm"},"events":[{"id":27070,"run_id":24641,"accession_number":"0001213900-26-088068","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The filing discloses the appointment of Jonathan Peri, Ph.D., J.D. as an independent director to Citius Oncology's Board, effective August 10, 2026, expanding the Board to nine members. The Board determined Dr. Peri qualifies as independent under Nasdaq listing standards and will be compensated under the Company's director compensation program. This is a clear executive/director appointment event under Item 5.02(d).","company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28439,"accession_number":"0001213900-26-088068","item_number":"5.02","item_title":"Departure of","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Jonathan Peri, Ph.D., J.D. as an independent director to Citius Oncology's Board, effective August 10, 2026, expanding the Board to nine members. The Board determined Dr. Peri qualifies as independent under Nasdaq listing standards and will be compensated under the Company's director compensation program. This is a clear executive/director appointment event under Item 5.02(d).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T12:31:41.494056+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28439,"accession_number":"0001213900-26-088068","item_number":"5.02","item_title":"Departure of","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Jonathan Peri, Ph.D., J.D. as an independent director to Citius Oncology's Board, effective August 10, 2026, expanding the Board to nine members. The Board determined Dr. Peri qualifies as independent under Nasdaq listing standards and will be compensated under the Company's director compensation program. This is a clear executive/director appointment event under Item 5.02(d).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T12:31:41.494056+00:00","company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","filing_date":"2026-08-12"}]}